Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 200

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Open access
Li, Xin, Cheng, Yasong, Zhang, Mingzhi, Yan, Jiaqin, Li, Ling, Fu, Xiaorui, Zhang, Xudong, Chang, Yu, Sun, Zhenchang, Yu, Hui, Zhang, Lei, Wang, Xinhua, Wu, Jingjing, Li, Zhaoming, Nan, Feifei, Tian, Li, Li, Wencai, Young, Ken H. · 2018 · Journal of Hematology & Oncology

Abstract

Natural killer/T-cell lymphoma (NKTCL) is a rare subtype of non-Hodgkin lymphoma that is associated with a poor outcome. Currently, the treatment needs of NKTCL remain unmet, and efforts to further improve treatment are urgently needed. Herein, seven patients with NKTCL who failed to respond to various types of chemotherapies were treated with the anti-programmed death 1 (anti-PD-1) antibody pembrolizumab at 100 mg every 3 weeks. After a median of four cycles of treatment (range 2-18), four out of seven patients responded (two complete response, two partial response, overall response rate 57%). Expression of PD1-ligand available was 50, 20, 30, 70, and 30% of five patients respectively. It is negative in one patient and not tested in one patient. Adverse events, which mostly ranged from grade I to grade III, were tolerable and could be safely handled, although immune-related pneumonitis was notable. Overall, PD-1 blockade with pembrolizumab represents a favorable strategy for the treatment of refractory/relapsed NKTCL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-018-0559-7

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 200

Metadata

Authors
Li, X., Cheng, Y., Zhang, M., Yan, J., Li, L., Fu, X., Zhang, X., Chang, Y., Sun, Z., Yu, H., Zhang, L., Wang, X., Wu, J., Li, Z., Nan, F., Tian, L., Li, W., & Young, K. H.
Venue
Journal of Hematology & Oncology
Published
2018-01-31
Volume
11
Issue
1
Pages
15-15
ISSN
1756-8722 (ISSN-L)
OpenAlex
W2792211393
Cited by
200
References
8
FWCI
15.75
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. https://app.cochat.ai/papers/10.1186/s13045-018-0559-7
The paper
Li, X., Cheng, Y., Zhang, M., Yan, J., Li, L., Fu, X., Zhang, X., Chang, Y., Sun, Z., Yu, H., Zhang, L., Wang, X., Wu, J., Li, Z., Nan, F., Tian, L., Li, W., & Young, K. H. (2018). Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-018-0559-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.